Table 3. Demographic and clinical characteristics of the study-population.
|
Total cohorta N = 83 |
Bloodstream infection etiologya | |||
|---|---|---|---|---|
|
Staphylococcus aureus n = 27 |
Streptococcus pneumoniae n = 30 |
Escherichia coli n = 26 |
||
| Demographic data | ||||
| Median age, years | 72 (24–93) | 77 (24–93) | 70 (30–89) | 76 (29–93) |
| Female | 39 (47) | 4(15) | 21 (70) | 14 (54) |
| Co-morbidities | ||||
| Ischemic heart disease | 24 (29) | 9 (33) | 6 (20) | 9 (35) |
| COPD | 6 (7) | 1 (4) | 5 (17) | 0 |
| Diabetes mellitus | 18 (22) | 6 (22) | 2 (7) | 10 (39) |
| Renal failure | 7 (8) | 3 (11) | 0 | 3 (12) |
| Active malignancy | 9 (11) | 3 (11) | 3 (10) | 3 (12) |
| Charlson’s score | 1 (0–8) | 1 (0–8) | 1 (0–8) | 2 (0–7) |
| Immuno-suppressive treatmentb | 8 (10) | 1 (4) | 3 (10) | 4 (15) |
| Clinical data | ||||
| Antibiotics before analyses | 6 (7) | 1 (4) | 0 | 5 (19) |
| Adequate initial antibiotic treatment | 80 (96) | 25 (93) | 30 (100) | 25 (96) |
| Body temperature,°C, at admission | 38.7 (35.6–41.0) | 38.6 (35.6–40.9) | 38.6 (35.8–41) | 39.1 (37.1–40.0) |
| SOFA score increase at admission | 1 (0–7) | 1 (0–7) | 2 (0–6) | 1 (0–7) |
| Sepsis (SOFA score increase ≥2) | 41 (49) | 13(48) | 22 (73) | 6 (23) |
| Hospitalization length, days | 8 (2–120) | 14 (3–120) | 5 (2–70) | 4 (2–25) |
| Intensive care unit admission | 16 (19) | 7 (26) | 7 (23) | 2 (8) |
| 90-days mortality | 10 (12) | 7 (26) | 1 (3) | 2 (8) |
| Focus of infection | ||||
| Endovascular | 7 (8) | 6 (22) | 0 | 1 (4) |
| Skin/soft tissue/bone | 16 (19) | 15 (55) | 1 (3) | 0 |
| Respiratory tract | 26 (31) | 1 (4) | 25 (83) | 0 |
| Gastrointestinal | 1 (1) | 0 | 0 | 1 (4) |
| Urinary tract | 21 (25) | 0 | 0 | 21 (81) |
| Central nervous System | 4 (5) | 0 | 4 (13) | 0 |
| Unknown | 8 (10) | 5 (19) | 0 | 3 (12) |
a Data are presented as numbers (percentages) for categorical variables and as median values (ranges) for continuous variables.
bMethotrexate, chemotherapeutics, or cortisol dosing equivalent to prednisolone ≥ 20mg.